Alterations of Nasal Mucociliary Clearance in Association with HIV Infection and the Effect of Guaifenesin Therapy
| Autor: | Elizabeth J. Rosen, Karen H. Calhoun |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Guaifenesin medicine.medical_specialty Mucociliary clearance HIV Infections Placebo law.invention Saccharin Double-Blind Method Randomized controlled trial Acquired immunodeficiency syndrome (AIDS) law Internal medicine Immunopathology medicine Humans Medical history Sinusitis Sida Expectorants biology business.industry virus diseases Middle Aged biology.organism_classification medicine.disease Nasal Mucosa Otorhinolaryngology Mucociliary Clearance Immunology Female business medicine.drug |
| Zdroj: | The Laryngoscope. 115:27-30 |
| ISSN: | 1531-4995 0023-852X |
| Popis: | To determine if human immunodeficiency virus (HIV) infection is associated with a prolonged mucociliary clearance time (MCT) and to evaluate the effect of guaifenesin on MCT in HIV+ patients.A cross-sectional study comparing HIV+ and HIV- volunteers followed by a prospective, randomized, double-blind, placebo-controlled study of HIV+ patients before and after guaifenesin treatment.Twenty-five HIV+ patients and 29 HIV- controls were enrolled and MCT was measured using the saccharin method. A separate group of 20 HIV+ patients participated in the second arm of the study and underwent saccharin testing before and after a 3-week course of guaifenesin or placebo. All study participants completed a medical history questionnaire, a sinonasal symptom (SNOT-16) survey, and were examined with both anterior rhinoscopy and rigid nasal endoscopy.There was a significant difference (P.002) in the MCT between the HIV+ group (13.3 +/- SD 7.5 minutes) and the HIV- controls (9.2 +/- SD 3.9 minutes). The difference in MCT between the guaifenesin and placebo groups did not reach statistical significance (P.05). The HIV+ group had a higher SNOT-16 score compared to HIV- controls (21.1 vs. 7.4, P.001). Guaifenesin therapy in HIV+ patients led to a significant improvement in the SNOT-16 score (P.05).Compared to HIV- controls, HIV+ patients have a prolonged MCT and more sinonasal symptoms as indicated by a higher SNOT-16 score. Guaifenesin therapy was associated with improved SNOT-16 scores, although there was not a detectable improvement in MCT. Use of guaifenesin in HIV+ patients with sinonasal disease may lead to improved patient perception of quality of life. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text